Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125200302 | 12520030 | 2 | F | 20160525 | 20160801 | 20160701 | 20160802 | EXP | FR-ROCHE-1785878 | ROCHE | 77.00 | YR | M | Y | 0.00000 | 20160802 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125200302 | 12520030 | 1 | PS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 375 MG/M2 THEN 500 MG/M2 IN 1 INJECTION PER MONTH | Y | 103705 | 1 | DF | SOLUTION FOR INFUSION | /month | |||||
| 125200302 | 12520030 | 2 | SS | ZYDELIG | IDELALISIB | 1 | Oral | Y | 0 | 150 | MG | BID | |||||||
| 125200302 | 12520030 | 3 | SS | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | Y | 0 | 500 | MG | QD | |||||||
| 125200302 | 12520030 | 4 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | Y | 0 | 200 | MG | QD | |||||||
| 125200302 | 12520030 | 5 | SS | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | Oral | AS REQUIRED. | Y | 0 | 10 | MG | |||||||
| 125200302 | 12520030 | 6 | SS | XARELTO | RIVAROXABAN | 1 | Oral | U | 0 | 15 | MG | QD | |||||||
| 125200302 | 12520030 | 7 | SS | FLECAINE | FLECAINIDE | 1 | Oral | U | 0 | 150 | MG | QD | |||||||
| 125200302 | 12520030 | 8 | C | BISOPROLOL | BISOPROLOL | 1 | 0 | ||||||||||||
| 125200302 | 12520030 | 9 | C | LERCANIDIPINE | LERCANIDIPINE | 1 | 0 | ||||||||||||
| 125200302 | 12520030 | 10 | C | ATORVASTATINE | ATORVASTATIN | 1 | Unknown | 0 | |||||||||||
| 125200302 | 12520030 | 11 | C | DERMOVAL (FRANCE) | 2 | Unknown | 3 TUBE A DAY FOR SYMPTOMATIC TREATMENT | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125200302 | 12520030 | 1 | Lymphoma |
| 125200302 | 12520030 | 2 | Lymphoma |
| 125200302 | 12520030 | 3 | Prophylaxis |
| 125200302 | 12520030 | 4 | Lymphoma |
| 125200302 | 12520030 | 5 | Nausea |
| 125200302 | 12520030 | 6 | Transient ischaemic attack |
| 125200302 | 12520030 | 7 | Transient ischaemic attack |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125200302 | 12520030 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125200302 | 12520030 | Dermatitis exfoliative |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125200302 | 12520030 | 1 | 20160104 | 20160525 | 0 | |
| 125200302 | 12520030 | 2 | 20160104 | 20160525 | 0 | |
| 125200302 | 12520030 | 3 | 201601 | 20160525 | 0 | |
| 125200302 | 12520030 | 4 | 201601 | 20160525 | 0 | |
| 125200302 | 12520030 | 5 | 201601 | 20160525 | 0 | |
| 125200302 | 12520030 | 6 | 20160104 | 0 | ||
| 125200302 | 12520030 | 7 | 20160104 | 0 | ||
| 125200302 | 12520030 | 10 | 20160607 | 0 |